arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Editas Medicine, Inc.

EDIT Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$2.36
▼ -6.0% Today
as of Oct 23, 14:17 ET
Last 30 days -13.14% Sep 14 → Oct 23
$2.22 $2.41 $2.60 $2.78 $2.97 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$2.47
High
$2.58
Low
$2.45
Volume
$1M
Avg Vol
$2M
Mkt Cap
$387M
P/E (TTM)
—
Beta
—
52w High
$3.94
52w Low
$1.66
Div Yield
—
Shares Out
$98M

Recent Press Releases & News last 60 days · 16 items

Oct 14 · 13:00 PR GlobeNewswire
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
Oct 9 · 14:53 Zacks
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
Oct 8 · 18:25 MT Newswires
Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401
▸ Show all 16 press releases & news Free account →

EDIT earnings at a glance

The options market is pricing a move of about ±24.8% after the report, a range of roughly $1.77 to $2.95 from today's $2.36. Over its last 2 reports the stock rose the next day 2 times and fell 0, moving ±3.8% on average; after the most recent report on May 5, 2026 it moved +1.3%. That means options currently expect more movement than EDIT has typically delivered. EDIT beat the consensus EPS estimate in 3 of its last 4 reported quarters. Implied volatility is currently 210%. The share price of $2.36 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.66
$3.94
31% of range
Avg surprise (last 4)
+0.4%
Avg reaction (last 2)
+3.8%
100% positive
Latest IV / EM
210%
EM ±24.8% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.82$-0.65$-0.48$-0.32$-0.15 Actual $-0.71Actual $-0.56Actual $-0.55Actual $-0.76Actual $-0.82Actual $-0.75Actual $-0.43Est $-0.51Actual $-0.63Est $-0.41Actual $-0.28Est $-0.38Actual $-0.26Est $-0.30Actual $-0.15 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-76M$-54M$-32M$-10M$12M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.15 — — — — financials
Tue May 5, 2026Mar/2026 $-0.26 $-0.30 +13.3% +39.5% +1.3% earnings
Mon Nov 10, 2025Sep/2025 $-0.28 $-0.38 +26.3% — — earnings
Tue Aug 12, 2025Jun/2025 $-0.63 $-0.41 -53.7% — — earnings
Mon May 12, 2025Mar/2025 $-0.43 $-0.51 +15.7% — +6.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.75 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.82 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.76 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.55 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.56 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.71 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$12M$3M—$8M$4M$5M—$61,000
Cost of revenue————————
Gross profit————————
Operating income$-19M$-25M—$-25M$-52M$-76M—$-66M
Net income$-18M$-25M—$-25M$-53M$-76M—$-62M
EPS (diluted)$-0.15$-0.26—$-0.28$-0.63$-0.92—$-0.75

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$182M$124M$147M$166M$139M$139M$132M$96M
Inventory————————
Total current assets$218M$128M$164M$177M$183M$225M$289M$271M
Total assets$237M$149M$187M$202M$211M$264M$342M$328M
Long-term debt$48M$47M$54M$54M$52M$50M$52M—
Total liabilities$132M$145M$159M$188M$191M$201M$207M$152M
Total equity$105M$4M$27M$13M$19M$62M$134M$176M

Implied volatility — last 90 days

38%251%464%677%891% Jun 07 — IV 200% · EM ±27.7%Jun 08 — IV 243% · EM ±32.1%Jun 09 — IV 138% · EM ±17.3%Jun 10 — IV 138% · EM ±16.3%Jun 11 — IV 157% · EM ±17.3%Jun 12 — IV 156% · EM ±16.0%Jun 15 — IV 168% · EM ±12.1%Jun 16 — IV 251% · EM ±14.8%Jun 17 — IV 236% · EM ±9.8%Jun 19 — IV 109% · EM ±24.2%Jun 22 — IV 111% · EM ±23.2%Jun 23 — IV 120% · EM ±24.5%Jun 24 — IV 116% · EM ±23.2%Jun 25 — IV 88% · EM ±17.3%Jun 26 — IV 96% · EM ±18.4%Jun 29 — IV 128% · EM ±22.7%Jun 30 — IV 139% · EM ±23.9%Jul 01 — IV 141% · EM ±23.6%Jul 02 — IV 191% · EM ±30.9%Jul 03 — IV 197% · EM ±30.8%Jul 06 — IV 425% · EM ±58.9%Jul 07 — IV 505% · EM ±66.7%Jul 08 — IV 489% · EM ±61.3%Jul 09 — IV 469% · EM ±55.4%Jul 10 — IV 514% · EM ±56.7%Jul 13 — IV 511% · EM ±42.7%Jul 14 — IV 525% · EM ±38.0%Jul 15 — IV 891% · EM ±52.6%Jul 16 — IV 499% · EM ±20.8%Jul 20 — IV 115% · EM ±27.2%Jul 21 — IV 97% · EM ±22.6%Jul 22 — IV 106% · EM ±24.2%Jul 23 — IV 110% · EM ±24.7%Jul 24 — IV 94% · EM ±20.8%Jul 27 — IV 54% · EM ±11.2%Jul 28 — IV 106% · EM ±21.8%Jul 29 — IV 106% · EM ±21.2%Jul 30 — IV 57% · EM ±11.1%Jul 31 — IV 91% · EM ±17.4%Aug 03 — IV 122% · EM ±21.7%Aug 04 — IV 115% · EM ±19.9%Aug 05 — IV 136% · EM ±22.7%Aug 06 — IV 112% · EM ±18.1%Aug 07 — IV 100% · EM ±15.6%Aug 10 — IV 39% · EM ±5.3%Aug 11 — IV 321% · EM ±42.4%Aug 12 — IV 98% · EM ±12.3%Aug 13 — IV 211% · EM ±24.9%Aug 14 — IV 193% · EM ±21.3%Aug 17 — IV 316% · EM ±26.4%Aug 18 — IV 312% · EM ±22.6%Aug 19 — IV 599% · EM ±35.4%Aug 20 — IV 774% · EM ±32.3%Aug 24 — IV 120% · EM ±25.0%Aug 25 — IV 268% · EM ±54.9%Aug 26 — IV 259% · EM ±51.9%Aug 27 — IV 271% · EM ±53.0%Aug 28 — IV 231% · EM ±44.3%Aug 31 — IV 240% · EM ±42.5%Sep 01 — IV 274% · EM ±47.2%Sep 02 — IV 282% · EM ±47.1%Sep 03 — IV 331% · EM ±53.6%Sep 04 — IV 287% · EM ±44.9%Sep 07 — IV 324% · EM ±44.9%Sep 08 — IV 350% · EM ±46.2%Sep 09 — IV 243% · EM ±30.5%Sep 10 — IV 112% · EM ±13.2%Sep 11 — IV 117% · EM ±13.0%Sep 14 — IV 175% · EM ±14.6%Sep 15 — IV 184% · EM ±13.3%Sep 16 — IV 344% · EM ±20.3%Sep 17 — IV 423% · EM ±17.7%Sep 21 — IV 102% · EM ±21.2%Sep 22 — IV 105% · EM ±21.4%Sep 23 — IV 97% · EM ±19.5%Sep 24 — IV 125% · EM ±24.5%Sep 25 — IV 85% · EM ±16.3%Sep 28 — IV 78% · EM ±13.9%Sep 29 — IV 73% · EM ±12.5%Sep 30 — IV 76% · EM ±12.6%Oct 01 — IV 110% · EM ±17.8%Oct 02 — IV 92% · EM ±14.3%Oct 06 — IV 153% · EM ±20.1%Oct 07 — IV 145% · EM ±18.2%Oct 08 — IV 210% · EM ±24.8%

Sector peers

ZURA
Zura Bio Limited
$397M $3.39-17.9%
AGEN
Agenus Inc.
$376M $6.32-1.3%
KYTX
Kyverna Therapeutics, Inc.
$403M $5.37-8.1%
FENC
Fennec Pharmaceuticals Inc.
$365M $10.02-3.5%
CCCC
C4 Therapeutics, Inc.
$347M $3.05-3.8%
OCGN
Ocugen, Inc.
$339M $0.74-8.8%

EDIT earnings FAQ

What is EDIT's expected move for earnings?

Options currently price a move of about ±24.8%, or $0.59 per share either way from $2.36.

How does EDIT stock usually react to earnings?

Across the last 2 reports the average next-day move was ±3.8%, up 2 times and down 0 times.

What is EDIT's implied volatility?

EDIT's at-the-money implied volatility is about 210% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in